POTENTIAL DRUG-DRUG INTERACTIONS OF CARDIOVASCULAR DRUGS BASED ON LITERATURE IN GERIATRIC PATIENTS WITH CONGESTIVE HEART FAILURE  AT Dr. M. DJAMIL PADANG HOSPITAL

DITA PERMATASARI; NUR ALIMA HUSNA; RAHMI YOSMAR

doi:10.22159/ijap.2024.v16s1.06

Authors

DITA PERMATASARI Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Andalas, Padang-25163, Indonesia https://orcid.org/0000-0002-9884-3668
NUR ALIMA HUSNA Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Andalas, Padang-25163, Indonesia https://orcid.org/0000-0002-5920-0360
RAHMI YOSMAR Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Andalas, Padang-25163, Indonesia https://orcid.org/0000-0002-9884-3668

DOI:

https://doi.org/10.22159/ijap.2024.v16s1.06

Keywords:

Potential drug-drug interactions, CHF, Geriatric, Cardiovascular drugs

Abstract

Objective: Congestive Heart Failure (CHF) is a notable cardiovascular disease impacting global morbidity and mortality. Geriatric patients with CHF typically require multiple medications that can potentially cause drug-drug interactions and affect patient therapy outcomes. This study aims to determine the potential drug-drug interactions, the relationship between the average number of cardiovascular drugs per day and the potential drug-drug interactions, and the relationship between the severity of drug-drug interactions and the clinical symptoms and signs of the patients.

Methods: The research method used was analytical observational with retrospective data collection through the medical records of inpatients in 2021. A total of 63 patients were included using the total sampling method.

Results: Results revealed that furosemide was the most commonly prescribed cardiovascular medication (15.27%). Among the participants, 93.65% exhibited potential drug-drug interactions (332 occurrences), with the most frequent involving furosemide and bisoprolol (32 cases). Pharmacodynamic interactions were the dominant mechanism (85.24%), with moderate severity (65.06%) being common. A significant relationship existed between the average number of cardiovascular drugs per day and the potential drug-drug interactions (p<0.05). Nonetheless, there was no notable correlation discovered between the severity of the interaction and the presence of symptoms and clinical signs (p>0.05).

Conclusion: When considering the high incidence of potential drug-drug interactions, it is expected that clinical pharmacists have the competence to analyze potential drug interactions to prevent harmful effects on patients.

Downloads

Download data is not yet available.

References

Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93-e621. doi: 10.1161/CIR.0000000000001123, PMID 36695182.

Kementerian kesehatan republik indonesia. Riset kesehatan dasar. jakarta: RISKESDAS, Balitbang Kemenkes RI; 2013.

Malik A, Frito D, SV. Congestive heart failure. Stat; 2021.

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM. AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines; 2022. doi: 10.1161/CIR.0000000000001063.

Lupitaningrum DM, Ramdaniah P, Yuliana D. Identification of adverse drug reactions in congestive heart failure patients in a tertiary Care Hospital, West Nusa Tenggara, Indonesia. Pharm Sci Res. 2021;8(1):47-54.

Espinosa Bosch M, Santos Ramos B, Gil Navarro MV, Santos Rubio MD, Marin Gil R, Villacorta Linaza P. Prevalence of drug interactions in hospital healthcare. Int J Clin Pharm. 2012;34(6):807-17. doi: 10.1007/s11096-012-9697-0, PMID 22965222.

Aidoud A, Gana W, Poitau F, Debacq C, Leroy V, Nkodo JA. High prevalence of geriatric conditions among older adults with cardiovascular disease. J Am Heart Assoc. 2023;12(2):e026850. doi: 10.1161/JAHA.122.026850, PMID 36628962.

Stefil M, Dixon M, Bahar J, Saied S, Mashida K, Heron O. Polypharmacy in older people with heart failure: roles of the geriatrician and pharmacist. Card Fail Rev. 2022;8:e34. doi: 10.15420/cfr.2022.14, PMID 36891063.

Rodrigues MCS, De Oliveira C. Drug-drug interactions and adverse drug reactions in polypharmacy among older adults: an integrative review. Rev Lat Am Enfermagem. 2016;24:e2800. doi: 10.1590/1518-8345.1316.2800, PMID 27598380.

Campeau Calfat A, Simard M, Ouali A, Blais C, Sirois C. Polypharmacy among older individuals with heart failure: trends between 2000 and 2017 in the province of Quebec, Canada. Ther Adv Cardiovasc Dis. 2022;16:17539447221113946. doi: 10.1177/17539447221113946, PMID 35875931.

Roblek T, Trobec K, Mrhar A, Lainscak M. Potential drug-drug interactions in hospitalized patients with chronic heart failure and chronic obstructive pulmonary disease. Arch Med Sci. 2014;10(5):920-32. doi: 10.5114/aoms.2014.46212, PMID 25395943.

Dumbreck S, Flynn A, Nairn M, Wilson M, Treweek S, Mercer SW. Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines. BMJ. 2015;350:h949. doi: 10.1136/bmj.h949, PMID 25762567.

Adondis J, Mongi J, Tiwow GAR, Palandi RR. Studi potensi interaksi obat pada pasien gagal jantung di instalasi rawat inap rumah sakit advent manado. Biofarmasetikal Tropis. 2019;2(2):124-35. doi: 10.55724/jbiofartrop.v2i2.125.

Baxter K. Stockley’s drug interactions. Pharmaceutical Press; 2010.

Tatro DS. Drug interaction facts. Wolters Kluwer Health; 2008.

Topol EJ. Medscape; 2023.

Kluwr W. Health, American Society of Health-System Pharmacists CM and, Health M from T. Drug Interaction Checker; 2023.

Heo S, Lennie TA, Okoli C, Moser DK. Quality of life in patients with heart failure: ask the patients. Heart Lung. 2009;38(2):100-8. doi: 10.1016/j.hrtlng.2008.04.002, PMID 19254628.

Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res. 2021;128(10):1421-34. doi: 10.1161/CIRCRESAHA.121.318172, PMID 33983838.

Bosch L, Assmann P, de Grauw WJC, Schalk BWM, Biermans MCJ. Heart failure in primary care: prevalence related to age and comorbidity. Prim Health Care Res Dev. 2019;20:e79. doi: 10.1017/S1463423618000889, PMID 31868152.

Young EH, Pan S, Yap AG, Reveles KR, Bhakta K. Polypharmacy prevalence in older adults seen in United States physician offices from 2009 to 2016. Plos One. 2021;16(8):e0255642. doi: 10.1371/journal.pone.0255642, PMID 34343225.

Maharani DD, Syafhan NF, Hersunaryati Y. Drug-related problems in hospitalized geriatric patients with diabetes mellitus. Int J App Pharm. 2018;10(1):142-7. doi: 10.22159/ijap.2018.v10s1.30.

Olii AT, Nurlina N, Niswah H. Profil peresepan obat pada pasien rawat jalan jamkesda dari poli kardiovaskular di apotek rumah sakit labuang baji makassar periode januari-juni 2014. Jurn As-Syifaa. 2014;6(2):154-65. doi: 10.33096/jifa.v6i2.45.

Nopitasari BL, Nurbaety B, Zuhroh H. Evaluasi penggunaan obat antihipertensi pada pasien gagal jantung rawat jalan di rumah sakit umum daerah provinsi nusa tenggara barat. Lumbung Farmasi J Ilmu Kefarmasian. 2020;1(2):66. doi: 10.31764/lf.v1i2.2542.

Paolillo S, Dell’Aversana S, Esposito I, Poccia A, Perrone Filardi P. The use of β-blockers in patients with heart failure and comorbidities: doubts, certainties and unsolved issues. Eur J Intern Med. 2021;88(Mar):9-14. doi: 10.1016/j.ejim.2021.03.035, PMID 33941435.

Beezer J, Al Hatrushi M, Husband A, Kurdi A, Forsyth P. Polypharmacy definition and prevalence in heart failure: a systematic review. Heart Fail Rev. 2022;27(2):465-92. doi: 10.1007/s10741-021-10135-4, PMID 34213753.

Diksis N, Melaku T, Assefa D, Tesfaye A. Potential drug-drug interactions and associated factors among hospitalized cardiac patients at Jimma University Medical Center, Southwest Ethiopia. SAGE Open Med. 2019;7:2050312119857353. doi: 10.1177/2050312119857353, PMID 31217972.

Akbar Z, Rehman S, Khan A, Khan A, Atif M, Ahmad N. Potential drug-drug interactions in patients with cardiovascular diseases: findings from a prospective observational study. J Pharm Policy Pract. 2021;14(1):63. doi: 10.1186/s40545-021-00348-1, PMID 34311787.

Sharma S, Chhetri HP, Alam K. A study of potential drug-drug interactions among hospitalized cardiac patients in a teaching hospital in Western Nepal. Indian J Pharmacol. 2014;46(2):152-6. doi: 10.4103/0253-7613.129303, PMID 24741184.

Fitria N, Wulansari S, Sari YO. Potential interactions analysis of antihypertensive drugs used in geriatric. Int J App Pharm. 2023;15Special Issue 1:29-33. doi: 10.22159/ijap.2023.v15s1.47503.

Annisa A, Timur WW. Hubungan interaksi obat pada pasien geriatrik rawat inap di rumah sakit islam sultan agung semarang periode 2020; 2022. p. 1-118.

Suryaman A. Hubungan polifarmasi dan interaksi obat pada pasien gagal jantung dengan komorbid gagal ginjal kronis di poliklinik jantung RSUD ulin banjarmasin tahun 2020-2021; 2023.

Kupper N, Bonhof C, Westerhuis B, Widdershoven J, Denollet J. Determinants of dyspnea in chronic heart failure. J Card Fail. 2016;22(3):201-9. doi: 10.1016/j.cardfail.2015.09.016, PMID 26435096.

Urbanek T, Jusko M, Kuczmik WB. Compression therapy for leg oedema in patients with heart failure. ESC Heart Fail. 2020;7(5):2012-20. doi: 10.1002/ehf2.12848, PMID 32710511.

Rullman E, Melin M, Mandic M, Gonon A, Fernandez Gonzalo R, Gustafsson T. Circulatory factors associated with function and prognosis in patients with severe heart failure. Clin Res Cardiol. 2020;109(6):655-72. doi: 10.1007/s00392-019-01554-3, PMID 31562542.